关键数据
5.400今开
5.465最高
842.71K成交量
亏损市盈率 TTM
亏损市盈率动
--股息TTM
2.04%换手率
5.370昨收
5.055最低
3.08M成交额
亏损市盈率静
0.81市净率
0.00%股息率 TTM
-15.12%ROA
26.38052周最高
0.89量比
-27.45M净利润
41.38M总股本
-1.1357每股收益TTM
1.21Beta
-17.06%ROE
5.90052周最低
7.64%振幅
76.06%毛利率
215.40M总市值
1.21回报/风险
3.86%风险率
操作建议
Rxsight Inc当前公司基本面数据相对健康,增长潜力较大。当前估值合理,在医疗设备与耗材行业排名69/200位。机构持股占比非常高,近一月多位分析师给出公司评级为持有。最高目标价8.57。中期看,股价处于下降通道。近一个月,市场表现一般,但基本面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。
压力支撑

由于公司未披露,未能获取相关数据
Rxsight Inc新闻
即将为您带来更多新闻,敬请期待。。。
收益预测
Zimmer Biomet Holdings Inc
ZBH
31
技术指标
财务指标
每股收益

由于公司未披露,未能获取相关数据
营业总收入

由于公司未披露,未能获取相关数据
Rxsight Inc简介
RxSight, Inc. is a commercial-stage medical technology company dedicated to providing customized vision to patients following cataract surgery. The Company's proprietary RxSight Light Adjustable Lens system (RxSight system) is commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system consists of its RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. In contrast, with the RxSight system, the surgeon implants the LAL during a standard cataract procedure, determines refractive error with patient input several weeks following surgery and then uses the LDD to modify the LAL with the precise visual correction needed to achieve the patient's desired vision outcomes.
公司代码RXST
公司Rxsight Inc
CEOKurtz (Ron M)
网址https://www.rxsight.com/
公司股东
常见问题
Rxsight Inc(RXST)的当前股价是多少?
Rxsight Inc(RXST)的当前股价是 5.39。
Rxsight Inc股票的52周最高点是多少?
Rxsight Inc股票的52周最高点是26.38。
Rxsight Inc股票的52周最低点是多少?
Rxsight Inc股票的52周最低点是5.90。
现在Rxsight Inc(RXST)的股票是买入、持有还是卖出?
根据分析师评级,Rxsight Inc(RXST)的总体评级为signal_hold,目标价格为8.57。
Rxsight Inc(RXST)股票的每股收益(EPS TTM)是多少
Rxsight Inc(RXST)股票的每股收益(EPS TTM)是-0.95。